A mathematical investigation of the multiple pathways to recurrent prostate cancer: comparison with experimental data.
Considerable research is aimed at determining the mechanisms by which hormone-refractory prostate cancer develops. In an effort to assist in the understanding of recurrent prostate cancer and the cellular processes that mediate this disease, a mathematical model is presented that describes both the pretreatment growth and the posttherapy relapse of human prostate cancer xenografts. Our goal is to evaluate the interplay between the multiple mechanisms that have been postulated as causes of androgen-independent relapse. Simulations of the model show that molecular events that render the androgen receptor irrelevant to disease progression, such as upregulation of BCL2, can result in relapse after androgen deprivation therapy. However, decreased apoptosis of androgen-independent cells alone overestimates the effects of hormone therapy when compared to experimental data. When decreased apoptosis is combined with continual androgen receptor activation, the posttherapy growth dynamics are in excellent correlation with experimental observations of the growth of LuCaP xenografts. Furthermore, the mathematical model predicts that upregulation of the androgen receptor, together with its increased activation, is alone sufficient to result in the androgen-independent growth of LNCaP xenografts. Recent experimental studies that suggest that the posttherapy increase in and continual activation of the androgen receptor are common and crucial features of recurrent prostate cancer provide validation of the model predictions. This approach provides a framework for using mathematical techniques to study novel therapeutic strategies aimed at controlling this disease.
Jackson
Trachette L
TL
Department of Mathematics, 525 E. University, University of Michigan, Ann Arbor, MI 48109-1109, USA. tjacks@umich.edu
D000728:Androgens / Q000378:metabolism; D000818:Animals; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D019008:Drug Resistance, Neoplasm / Q000502:physiology*; D006801:Humans; D008297:Male; D008962:Models, Theoretical; D009364:Neoplasm Recurrence, Local / Q000473:pathology*; D011471:Prostatic Neoplasms / Q000473:pathology*; D011944:Receptors, Androgen / Q000378:metabolism; D014183:Transplantation, Heterologous
D000728:Androgens; D011944:Receptors, Androgen
Urology. 1999 Dec;54(6A Suppl):1-7
10606277
Semin Surg Oncol. 2000 Jan-Feb;18(1):52-74
10617897
Math Biosci. 2000 Mar;164(1):17-38
10704636
CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33
10735013
J Urol. 2000 Dec;164(6):1992-5
11061898
Cancer Res. 2001 Jun 1;61(11):4315-9
11389051
J Androl. 2001 Jul-Aug;22(4):537-48
11451350
Prostate. 2002 Mar 1;50(4):222-35
11870800
Curr Opin Oncol. 2002 May;14(3):286-91
11981273
Clin Endocrinol (Oxf). 2002 Jun;56(6):779-86
12072048
J Math Biol. 2002 Mar;44(3):201-26
12148489
J Clin Endocrinol Metab. 2003 Jul;88(7):2972-82
12843129
N Engl J Med. 2003 Jul 24;349(4):366-81
12878745
Nat Med. 2004 Jan;10(1):33-9
14702632
J Biol Chem. 2004 Feb 20;279(8):7119-30
14662770
J Theor Biol. 1976 Jan;56(1):229-42
1263527
Int J Cancer. 1996 Jan 3;65(1):85-9
8543402
Cell Prolif. 1996 Jun;29(6):269-88
8809120
J Neuropathol Exp Neurol. 1997 Jun;56(6):704-13
9184661
Clin Cancer Res. 1995 May;1(5):473-80
9816006
Clin Cancer Res. 1996 Jun;2(6):1039-48
9816265
Int J Cancer. 1996 Sep 17;67(6):785-90
8824549